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Abstract
Background/Purpose: The effect of low-dose bisphenol A (BPA) exposure on human reproductive health is still
controversial. To better understand the molecular basis of the effect of BPA on human reproductive health, a genome-wide
screen was performed using human foreskin fibroblast cells (hFFCs) derived from child hypospadias (HS) patients to identify
novel targets of low-dose BPA exposure.
Methodology/Principal Findings: Gene expression profiles of hFFCs were measured after exposure to 10 nM BPA, 0.01 nM
17b-estradiol (E2) or 1 nM 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) for 24 h. Differentially expressed genes were
identified using an unpaired Student’s t test with P value cut off at 0.05 and fold change of more than 1.2. These genes were
selected for network generation and pathway analysis using Ingenuity Pathways Analysis, Pathway Express and KegArray.
Seventy-one genes (42 downregulated and 29 upregulated) were identified as significantly differentially expressed in
response to BPA, among which 43 genes were found to be affected exclusively by BPA compared with E2 and TCDD. Of
particular interest, real-time PCR analysis revealed that the expression of matrix metallopeptidase 11 (MMP11), a well-known
effector of development and normal physiology, was found to be inhibited by BPA (0.47-fold and 0.37-fold at 10 nM and
100 nM, respectively). Furthermore, study of hFFCs derived from HS and cryptorchidism (CO) patients (n=23 and 11,
respectively) indicated that MMP11 expression was significantly lower in the HS group than in the CO group (0.25-fold,
P=0.0027).
Conclusions/Significance: This present study suggests that an involvement of BPA in the etiology of HS might be
associated with the downregulation of MMP11. Further study to elucidate the function of the novel target genes identified
in this study during genital tubercle development might increase our knowledge of the effects of low-dose BPA exposure
on human reproductive health.
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Introduction
Hypospadias (HS) is one of the most common congenital
abnormalities with a global prevalence of approximately 0.2–1%
at birth in male infants [1]. The etiology of HS is poorly
understood, and might include genetic, hormonal and environ-
mental factors. It has been hypothesized that testicular cancer,
cryptorchidism (CO) and some cases of HS and impaired
spermatogenesis are symptoms of a single underlying entity that
has been named as the testicular dysgenesis syndrome (TDS) [2,3].
This concept proposes the existence of a common underlying
cause for the occurrence of these reproductive and developmental
diseases, and suggests that adverse environmental factors, such as
environmental endocrine disruptors (EEDs) might exert their
etiological effects on a susceptible genetic background.
Bisphenol A (BPA) is one of the world’s highest production-
volume chemicals, with more than six billion pounds produced
worldwide each year [4]. BPA is used extensively in the plastics
produced for food and beverage containers, such as baby bottles,
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known estrogen-like EEDs, BPA has received much attention
because it is commonly found in the environment as well as in
human tissues and fluids (1–19.4 nM) [4,5]. BPA has been
detected in 92% of urine samples in a US reference population,
suggesting people may be continuously exposed to this compound
in their daily lives [6]. The US Food and Drug Administration and
Environmental Protection Agency concluded in the 1980s that a
daily dose of 50 mg/kg/day was safe for humans, which is
currently considered as ,2.19610
27 M for in vitro cell or organ
culture studies [7]. However, in recent decades, there has been a
heated controversy over the safety of BPA among scientists and
risk assessors.
Recently, exposure to BPA at concentrations detected in
humans has been reported to affect neurological, cardiovascular
and metabolic diseases (such as diabetes), and even cancers [8–12].
However, the effect of low-dose BPA exposure on human
reproductive health is still controversial [13,14]. Li et al. reported
that occupational exposure to BPA has adverse effects on male
sexual dysfunction, which is the first evidence that exposure to
BPA in the workplace could have an adverse effect on male sexual
dysfunction [15]. Jasarevic et al. reported that exposure to BPA at
low doses can affect sexual behaviors, even with no changes in
sexual phenotypes or hormones [16]. Furthermore, Zhang et al.
reported that low-dose BPA exposure could directly disrupt
steroidogenesis in human cells [17]. It seems that exposure to
BPA might affect human reproductive health by complicated
mechanisms that encompass more than just estrogen receptor (ER)
mediated pathways.
In this study, to better understand the molecular basis of the
effects of BPA on human reproductive health, a genome-wide
screen was performed using human foreskin fibroblast cells
(hFFCs) derived from child HS patients to identify novel targets
of low-dose BPA exposure. Furthermore, the effect of BPA on the
global gene expression profile of hFFCs was compared with that of
17b-estradiol (E2) and 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), which are representative agonists of ER and aryl
hydrocarbon receptor (AhR) signaling pathways, respectively.
Materials and Methods
Samples
hFFCs from child HS (n=23; median age 2.3 yrs) and CO
(n=11; median age 2.3 yrs) patients undergoing surgical proce-
dures were obtained from the National Research Institute for
Child Health and Development, Japan, during 2007–2009. All
subjects were of Japanese origin and written informed consent was
obtained from the guardians on the behalf of the children
participants involved in this study. This study was approved by the
Institutional Ethics Committees of the Nagoya City University
Graduate School of Medical Sciences, the National Research
Institute for Child Health and Development and the National
Institute for Environmental Studies.
Chemicals
Dimethyl sulfoxide (DMSO) and E2 were obtained from Sigma
Chemical Co. (St. Louis, MO, USA). BPA was obtained from
Wako Industries (Osaka, Japan) and TCDD was obtained from
Cambridge Isotope Laboratories (Cambridge, MA, USA). DMSO
was used as the primary solvent for all chemicals, and the DMSO
solutions were further diluted in cell culture media for treatments.
The final concentrations of DMSO in media did not exceed 0.1%
(vol/vol).
Cell culture
hFFCs were maintained in Dulbecco’s Modified Eagle Medium
(DMEM)/Ham’s F-12 (048-29785, Wako, Osaka, Japan) contain-
ing 10% fetal bovine serum (FBS, Mediatech, Herndon, VA, USA)
and grown at 37uC in a 5% CO2 humidified incubator. For
growth under steroid-free conditions, cells were seeded in phenol
red-free DMEM/Ham’s F-12 (045-30665, Wako) containing 5%
Table 1. Summary of genes differentially expressed in
response to BPA, E2 and TCDD.
BPA E2 TCDD
P-value 1.0-fold 1.2-fold 1.0-fold 1.2-fold 1.0-fold 1.2-fold
0.05 154 71
* 1101 814
* 1150 824
*
0.01 30 17 198 154 208 156
0.001 7 5 16 11 14 9
*Selected as significant differentially expressed genes and used for the network
generation and pathway analysis.
doi:10.1371/journal.pone.0036711.t001
Figure 1. Genetic response of hFFCs to BPA, E2 and TCDD. (A)
Venn-diagrams showing the number of genes that were considered
significantly deregulated among the three treatment groups. (B) PCA
scoreplot from transcript data of three hFFC cultures treated with
DMSO, 10 nM BPA, 0.01 nM E2 and 1 nM TCDD.
doi:10.1371/journal.pone.0036711.g001
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culture media contained 100 U/ml penicillin/streptomycin and
2 mmol/L L-glutamine (Mediatech, Herndon, VA, USA).
RNA isolation and DNA microarray analysis
Total RNA was isolated from cultured cells after treatment with
chemicals for 24 h using an RNeasy Kit (Qiagen, Valencia, CA,
USA) in accordance with the manufacturer’s instructions. Quan-
tification and quality assessment of the isolated RNA samples were
performed and verified using an Agilent Bioanalyzer2100 (Agilent
Technologies, Palo Alto, CA, USA) and a NanoDrop spectro-
photometer (NanoDrop products, Wilmington, DE, USA) in
accordance with the manufacturer’s instructions. RNA was
amplified into cRNA and labeled according to the Agilent One-
Color Microarray-Based Gene Expression Analysis protocol
(Agilent Technologies). Samples were then hybridized to
G4851A SurePrint G3 Human GE 8660K array slides (60,000
probes, Agilent Technologies). The slides were processed accord-
ing to the manufacturer’s instructions without any modification.
The arrays were scanned using an Agilent Microarray Scanner
(G2565BA, Agilent Technologies).
MIAME
All data are MIAME compliant, and the raw data have been
deposited in the Gene Expression Omnibus (www.ncbi.nlm.nih.
gov/geo, accession no. GSE35034).
Array data analysis
The scanned images were analyzed using the standard
procedures described in the Agilent Feature Extraction software
9.5.3.1 (Agilent Technologies). Data analysis was performed with
GeneSpring GX12.0.2 (Agilent Technologies). Signal intensities
for each probe were normalized to the 75th percentile without
baseline transformation. Genes that were differentially expressed
following chemical treatments were identified by the unpaired
Student’s t test with P values cut off at 0.05 and fold change of
more than 1.2 and were used for the network generation and
pathway analysis.
Network generation and pathway analysis
The Ingenuity Pathways Analysis (IPA) program (Ingenuity
Systems, Mountain View, CA, USA; http://www.ingenuity.com)
was used to identify networks and canonical pathways of genes
differentially expressed in response to BPA, E2 and TCDD. IPA
software uses an extensive database of functional interactions that
are drawn from peer-reviewed publications and manually
maintained [18]. For the IPA analysis, the Agilent SurePrint G3
Human GE 8660 K Array was used as a reference gene set. The
generated biological networks were ranked by score, which is the
likelihood of a set of genes being found in the networks owing to
random chance, identified by a Fisher’s exact test. The generated
canonical pathways were ranked by P values, which is calculated
using a Fisher’s exact test by comparing the number of user-
specified genes of interest that participate in a given function or
pathway, relative to the total number of occurrences of these genes
in all functional/pathway annotations stored in the Ingenuity
Figure 2. Network associated genes differentially expressed in response to BPA. (A) ‘‘Endocrine System Disorders, Gastrointestinal Disease,
Genetic Disorder’’ network and (B) ‘‘Cell Death, Cellular Growth and Proliferation, Cancer’’ network. The images were created using the IPA platform
by overlaying the differentially expressed genes in response to BPA detected by Agilent microarray analysis onto a global molecular network from the
Ingenuity knowledgebase. Red indicates upregulated genes, green indicates downregulated genes, and white indicates genes that were not
annotated in this array but that form part of this network. The bottom numbers indicate the fold changes induced by BPA, and the top numbers are
the P-values between the DMSO control group and the BPA treated group. Direct relationships are exhibited with solid arrows and indirect
relationships with dashed arrows.
doi:10.1371/journal.pone.0036711.g002
Table 2. Top five associated network functions of genes differentially expressed in response to BPA, E2 and TCDD generated by
IPA.
Chemical Top Functions Score
BPA Endocrine System Disorders, Gastrointestinal Disease, Genetic Disorder 41
Cell Death, Cellular Growth and Proliferation, Cancer 21
Cellular Growth and Proliferation, Hematological System Development and Function, Cellular Development 18
Cellular Assembly and Organization, Cellular Function and Maintenance, Cell Cycle 13
Dermatological Diseases and Conditions, Inflammatory Disease 3
E2 Cellular Growth and Proliferation, Skeletal and Muscular System Development and Function, Cell Cycle 41
DNA Replication, Recombination, and Repair, Gene Expression, Cellular Assembly and Organization 41
Cellular Assembly and Organization, Cellular Function and Maintenance, Protein Synthesis 41
Gene Expression, Cell Cycle, Cell-To-Cell Signaling and Interaction 35
DNA Replication, Recombination, and Repair, Nucleic Acid Metabolism, Small Molecule Biochemistry 33
TCDD Post-Translational Modification, Genetic Disorder, Hematological Disease 49
Cell Cycle, Cellular Assembly and Organization, DNA Replication, Recombination, and Repair 47
Cellular Assembly and Organization, DNA Replication, Recombination, and Repair, Decreased Levels of Albumin 45
DNA Replication, Recombination, and Repair, Energy Production, Nucleic Acid Metabolism 44
DNA Replication, Recombination, and Repair, Cell Cycle, Cellular Assembly and Organization 37
doi:10.1371/journal.pone.0036711.t002
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differentially expressed in response to BPA, E2 and TCDD was
analyzed by Pathway Express (http://vortex.cs.wayne.edu/
projects.htm) and mapped to Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways by KegArray (http://www.kegg.jp/
kegg/download/kegtools.html).
Quantitative real-time reverse-transcription polymerase
chain reaction (RT-PCR)
cDNA was synthesized using a High Capacity RNA-to-cDNA
Kit (Applied Biosystems, Foster City, CA, USA) according to the
manufacturer’s instructions. Real-time PCR was performed using
TaqManH Gene Expression Master Mix (Applied Biosystems) in
accordance with the manufacturer’s instructions. TaqManH Gene
Expression Assays (Applied Biosystems) used in this study were:
Hs02341150_m1 for POMZP3, Hs01094348_m1 for WDR3,
Hs00171829_m1 for metallopeptidase 11 (MMP11; see gene
names in Table S1), and Hs00266705 g1 for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). The primers (Forward: 59-
TGTTGGGGGATAAGGACAAA-39; and Reverse: 59-
GCAGGCTGTACAGGAACCAT-39) and probe (59-TAAACT-
CACCTCTGTGGTTGGAACAAT-39) for NEK10 were de-
signed and synthesized by Hokkaido System Science (Sapporo,
Hokkaido, Japan). The amplification reaction was performed in an
ABI PRISM 7000 Sequence Detector (Applied Biosystems) under
the following cycling conditions: 95uC for 15 min, followed by 40
cycles of 95uC for 15 s and 60uC for 60 s. The gene expression
levels were calculated based on the threshold cycle using Sequence
Detection System Software (Applied Biosystems). Gene expression
was normalized to that of GAPDH and set to 100 for the control
DMSO-treated cells.
Statistical and multivariate analysis
Quantitative data were expressed as the mean 6 SEM. A
nonparametric test, the Mann-Whitney U test, was applied to test
for statistical significance. Values of P,0.05 were considered to
indicate statistical significance. Unsupervised principal component
analysis (PCA) was run in SIMCA-P+ (Version 12.0, Umetrics,
Umea ˚, Sweden) to obtain a general overview of the variance of
genes differentially expressed in response to BPA, E2 and TCDD.
Results
Gene expression profiles of hFFCs in response to BPA, E2
and TCDD
The gene expression profiles in hFFCs treated with DMSO
control or 10 nM BPA, 0.01 nM E2 or 1 nM TCDD were
determined by Agilent microarray analysis using three biological
replicates. Then, differentially expressed genes in response to BPA,
E2 and TCDD compared with DMSO control were identified by
the unpaired Student’s t test with P values cut off at 0.05 and fold
change of more than 1.2 using GeneSpring GX software. Seventy-
one genes (42 downregulated and 29 upregulated), 814 genes (371
downregulated and 443 upregulated), and 824 genes (344
downregulated and 480 upregulated) were identified to be
significantly differentially expressed in response to BPA, E2, and
TCDD, respectively. No nuclear receptor was found to be
significantly differentially expressed in response to BPA, while
estrogen-related receptor-a (ESRRA), retinoic acid receptor-a
(RARA) and RAR-related orphan receptor-a (RORA) and RARA
were found to be significantly differentially expressed in response
to E2 and TCDD, respectively. The summary of differentially
expressed genes along with their P values and fold changes is
provided in Table 1.
Differences in the response of hFFCs to BPA, E2 and
TCDD
Comparison of the gene expression profiles of hFFCs in
response to BPA, E2 and TCDD is provided in Figure 1. BPA-
specific responses were found in 43 significantly differentially
expressed genes, compared with responses to E2 and TCDD
(Figure 1A). Seventeen and 10 differentially expressed genes were
found to be common in response to BPA with E2 or TCDD,
respectively. A full list of these genes is summarized in Table S1.
Furthermore, to compare the expression patterns of hFFCs in
response to BPA with that of E2 or TCDD, PCA analysis was
performed on the data of significantly differentially expressed
genes in response to BPA. PCA is a standard technique of pattern
recognition and multivariate data analysis. Of interest, the cells
treated with DMSO, BPA, E2 and TCDD were clearly
distinguished from each other by the PCA score plots
(Figure 1B). According to the first component (PC1), which
represents 33.9% of the total variance, a very clear discrimination
between cells treated with BPA or E2 and those treated with
DMSO or TCDD was observed. However, according to the
second component (PC2), which represents 22.5% of the total
variance, cells treated with BPA or TCDD were clearly
distinguished from those treated with DMSO or E2. It should
be noted that differences in the PCA were identified using an
unsupervised analysis, without any prior information on the
samples. Since all cells were cultured under identical conditions,
the observed discriminations demonstrate that the effect of BPA is
similar to that of E2 according to PC1 but is similar to that of
TCDD according to PC2.
Table 3. Top canonical pathways for genes differentially
expressed in response to BPA, E2 and TCDD identified by IPA.
Chemical Top canonical pathway P-Value
BPA RAN Signaling 5.31E-02
Endoplasmic Reticulum Stress Pathway 6.34E-02
Leukocyte Extravasation Signaling 1.24E-01
Retinoic acid Mediated Apoptosis
Signaling
1.54E-01
Colorectal Cancer Metastasis Signaling 1.93E-01
E2 Cell Cycle: G1/S Checkpoint Regulation 1.01E-03
PI3K/AKT Signaling 1.52E-03
Role of NFAT in Regulation of the
Immune Response
1.83E-03
p53 Signaling 3.46E-03
Aryl Hydrocarbon Receptor Signaling 3.63E-03
TCDD Cell Cycle Control of Chromosomal
Replication
1.20E-09
Role of BRCA1 in DNA Damge Response 1.72E-07
Mismatch Repair in Eukaryotes 2.47E-05
Hereditary Breast Cancer Signaling 9.45E-04
Role of CHK Proteins in Cell Cycle
Checkpoint Control
1.00E-02
doi:10.1371/journal.pone.0036711.t003
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differentially expressed in response to BPA, E2 and TCDD
To investigate possible biological interactions of differently
regulated genes, datasets derived from microarray analysis
representing genes with altered expression profiles were imported
into the IPA platform. Network analysis of the biological functions
of the top five IPA-generated networks is summarized in Table 2
and is shown in Figure 2 and Figure S1,S2,S3.The two most highly
populated biological networks entitled ‘‘Endocrine System Disor-
ders, Gastrointestinal Disease, Genetic Disorder’’ (Score=41) and
‘‘Cell Death, Cellular Growth and Proliferation, Cancer’’
(Score=21) were identified with genes differentially expressed in
response to BPA (Figure 2). The networks consisted of genes that
encoded enzymes (ACER2, PLSCR1, POLR1C, TXNL4B and
UBC), peptidases (MMP11, UCHL5, USP4, USP36 and USP43),
proteins that regulate transcription (ABCA7, CRTC1, HNF4A,
LOC728622/SKP1, PHB, SF1 and SLC25A6) and translation
(EIF4ENIF1 and TNFRSF10C), and others (ARHGAP21,
ARRB2, CCDC41, CCDC134, EIF2AK3, EPB41L4A, DAZAP2,
EPB41L3, EXD3, FBXO18, FBXW12, FSIP1, JRKL, LGALS7/
LGALS7B, NEK10, NUDCD1, RAPGEF3, SERPINA1, WDR3,
WNT3A, ZNF222, ZNF224 and ZNF461). The most highly
populated biological networks were identified with genes differen-
tially expressed in response to E2 and TCDD and were entitled
‘‘Cellular Growth and Proliferation, Skeletal and Muscular System
Development and Function, Cell Cycle’’ (Score=41) and ‘‘Post-
Translational Modification, Genetic Disorder, Hematological
Disease’’ (Score=49), respectively. Furthermore, top canonical
pathways associated with genes significantly differentially ex-
pressed in response to BPA, E2 and TCDD were summarized in
Table 3. The pathway most affected by BPA is ‘‘RAN Signaling’’
with only borderline significance (P=0.0531). The pathways most
affected by E2 and TCDD are ‘‘Cell Cycle: G1/S Checkpoint
Regulation’’ and ‘‘Cell Cycle Control of Chromosomal Replica-
tion’’, respectively (P=1.01610
23 and 1.20610
29, respectively).
In addition, a list of top KEGG pathways affected by BPA, E2
and TCDD identified by Pathway Express was summarized in
Table S2. By inputting the list of genes significantly differentially
expressed in response to BPA, E2 and TCDD into Pathway
Express, 12 KEGG pathways, but without statistical significance,
were found to be affected by BPA, while 27 and 9 KEGG
pathways were found to be significantly affected by E2 and
TCDD, respectively. As an example, ‘‘Pathways in cancer’’ of
KEGG mapped with genes significantly differentially expressed in
response to BPA, E2 and TCDD using KegArray was illustrated in
Figure S4.
Validation by real-time PCR
To validate the microarray data and to identify potential
biomarkers for BPA toxicity in hFFCs derived from HS patients,
the expression of the most up- or down-regulated genes
(POMZP3, 1.46-fold; WDR3, 1.45-fold; NEK10, 0.44-fold;
Figure 3. Validation of POMZP1, WDR3, NEK10 and MMP11 expression. Cells were treated with BPA at 10 nM and 100 nM for 24 h, and
then the expression of POMZP1, WDR3, NEK10 and MMP11 was examined by real-time PCR. *P,0.05 vs. DMSO control cells.
doi:10.1371/journal.pone.0036711.g003
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PCR. As the results show in Figure 3, the PCR data showed good
concordance with the microarray data in terms of the expression
direction (up- or down-regulation). A significant increase in the
mRNA levels of POMZP3 and WDR3 and a significant decrease
in the mRNA levels of NEK10 and MMP11 were observed
following BPA treatments at high and/or low concentrations
(10 nM and 100 nM, respectively).
Comparison of MMP11 expression levels in hFFCs
derived from child HS and CO patients
To further investigate the potential role of MMP11 in the
development of HS, we examined the expression levels of MMP11
in hFFCs derived from child HS and CO patients (n=23 and 11,
respectively). As shown Figure 4, the mean MMP11 expression
level, normalized to GAPDH, in the HS group was 0.0015 and in
the CO group, 0.0058. Significantly lower MMP11 expression
levels were observed in the HS group compared with the CO
group (0.25-fold, P=0.0027).
Discussion
To better understand the molecular basis of the effects of BPA
on human reproductive health, target genes of low-dose BPA
exposure were identified in hFFCs derived from child HS patients
using DNA microarray analysis. Human foreskin tissues obtained
from patients with HS have been used as in vitro models to define
the etiology of HS [20–22]. However, these investigations have not
delineated the relative contribution of environmental factors. To
our knowledge, our study is the first report to use hFFCs to
investigate the potential effects of BPA on the development of HS.
The concentration of BPA used to treat the cells in our microarray
analysis was 10 nM, which is below the dose of 50 mg/kg/day
(approximately 200 nM for in vitro cell or organ culture studies)
usually considered as safe for humans [7]. Moreover, this dose is in
the concentration range of 1–19.4 nM that is commonly detected
in human tissues and fluids [4].
In this study, we compared the gene expression profiles of
hFFCs in response to BPA, E2 and TCDD. Using PCA, we found
that the effect of BPA is similar to that of E2 according to PC1 but
is similar to that of TCDD according to PC2. Forty-three genes
were found to be affected exclusively by BPA, underscoring the
concept that the effects observed are ER and AhR-independent
(Figure 1). In our previous study, we examined the estrogenic
activity of BPA in estrogen receptor 1 (ESR1)-positive BG1Luc4E2
human ovarian cancer cells and found that BPA increased the
ESR1-induced luciferase activity in a dose-dependent manner with
a lowest observed effect at 100 nM [23]. Although differences exist
between cell lines, it is possible that the underlying mechanisms of
the endocrine-disrupting effects of BPA at doses lower than the
reference limits might involve pathways other than estrogen
signaling. Indeed, differences in transcript profiles in response to
BPA and E2 have been previously described in ESR1-positive
human cells [24]. Furthermore, amore recent study reported that
BPA might lead to severe malformation during vertebrate
embryogenesis, while no effects were seen with exposure to the
E2 or ER-antagonist ICI 182,780 [25].
It is not unexpected that the largest biological network identified
by IPA analysis with genes differentially expressed in response to
BPA was entitled ‘‘Endocrine System Disorders, Gastrointestinal
Disease, Genetic Disorder’’ (Table 2 and Figure 2A). It should be
noted that this network contains three genes (ZNF222, ZNF224
and ZNF461) that belong to the zinc finger protein (ZFP) family.
ZFPs are among the most abundant proteins in eukaryotic
genomes and play various roles in the regulation of transcription
[26]. The biological function of ZNF222 and ZNF461 remains to
be investigated, but ZNF224 participates in key cellular processes,
such as regulation of cell growth [27]. Previous reports have
revealed that ZNF224 might play a critical role in bladder
carcinogenesis by regulating the apoptosis of bladder cancer cells
[28]. None of these three ZNFs have been previously associated
with the development of HS. However, two other zinc finger box
genes, ZEB1 and ZEB2, have been associated with HS [20,29].
Our data indicate that ZFP-mediated transcriptional activity
might be required for the effect of BPA on human reproduction. It
is known that zinc finger structures are as diverse as their functions
[26]. Therefore, it is likely that further investigations into the
function of ZFPs in transcriptional regulation will provide novel
insights to explain the association we found between ZFP
expression and low-dose BPA exposure regarding the pathogenesis
of HS.
The expression of four of the significantly differentially
expressed genes identified in the microarray analysis was verified
by real-time PCR analysis. Of particular interest, MMP11 (0.47-
fold and 0.37-fold at 10 nM and 100 nM, respectively), which is
involved in the ‘‘Cell Death, Cellular Growth and Proliferation,
Cancer’’ network, was shown to be down-regulated (Figures 2B
and 3). The matrix metalloproteinases (MMPs) are zinc-dependent
endopeptidases that are involved in the breakdown of extracellular
matrix (ECM) in normal physiological processes, such as
embryonic development, reproduction, and tissue remodeling, as
well as in disease processes, such as arthritis and metastasis
[30,31]. It is well known that MMP11 is overexpressed in several
human cancers, including breast, cervix, colon, ovary, prostate,
Figure 4. Reduced levels of MMP11 expression in hFFCs
derived from child HS patients. Significantly lower MMP11
expression was observed in hFFCs derived from the HS (n=23) group
compared with the CO (n=11) group by TaqMan real-time PCR. (A)
Boxplot and (B) summary of the quantitative data comparing MMP11
expression levels in HS and CO groups.
doi:10.1371/journal.pone.0036711.g004
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implicated in ECM degradation associated with tumor growth and
angiogenesis, which is required for a cancer cell to invade a nearby
blood vessel (intravasation) and then to extravasate at a distant
location and invade the distant tissue in order to seed a new
metastatic site [35].
To our knowledge, there have not been any reports of human
congenital genital disorders associated with MMP11. However, it
has been reported that MMPs play a critical role in cell fate and
behavior during many developmental processes [31,36]. Both
genetic analysis using transgenic mice and pharmacogenetic
studies with chemical inhibitors have elucidated that loss of
function of MMPs, in particular MMP11, might induce dysreg-
ulation in cell migration and apoptosis during tissue remodeling or
branching of mammary epithelial cells [37,38]. A more recent
study in the model insect, Tribolium, explored MMP functions in
vivo and found that knockdown of MMPs using genetic interfer-
ence resulted in malformation in tracheal and gut development
during beetle embryogenesis and pupal morphogenesis [39]. It is
known that epithelial seam formation and remodeling during
urethral formation play important roles in the etiology of HS. The
urethral abnormalities seen in HS can be viewed as a failure of
epithelial cell adhesion [40]. Therefore, we hypothesized that
downregulation of MMP11 expression might decrease cellular
adhesion in the developing male urethra and ventral penile skin,
which might result in the abortive penile development seen in HS.
To further confirm this hypothesis, we compared the expression
levels of MMP11 in hFFCs derived from child HS and CO patients
(n=23and11,respectively).In2001,Skakkebaekandhiscolleagues
proposed a concept of TDS: impaired development of fetal testes
could lead to increased risks of CO, HS, decreased spermatogenesis
or testicular cancer [2]. However, they have recently changed their
opinion and now suggest that HS is only marginally associated with
TDS [3]. Although much remains to be determined, it is likely that
the molecular etiology of HS and CO is different. CO is the absence
of one or both testes from the scrotum and is the most common
congenital abnormality in boys with a reported prevalence at birth
of approximately 2–9%, according to registry data [41]. Impaired
descent of the testes is thought to be fetal in origin, and if the in utero
development of the testicles is impaired then their production of
insulin-like factor 3 and especially testosterone may be reduced,
which may lead to some degree of CO [3,42]. However, it is likely
that isolated HS may have a different etiological mechanism,
including a congenital developmental problem restricted to the
penis [43]. Rey et al. found that most boys (85%) with isolated HS
had, in general, normal testicular endocrinology in contrast to those
with HS combined with other genital abnormalities [44]. In this
study, only child HS and CO patients without other genital
malformations of syndromes were recruited. Therefore, hFFCs
derived from foreskin tissues of child CO patients might be viewed
as the control group in this study. We found that MMP11
expression in the HS group was significantly lower than in the CO
group (0.25-fold, P=0.0027) (Figure 4). This result is in accordance
with our hypothesis that downregulation of MMP11 expression
might be related with the pathology of HS. Although the urethral
tissue was not directly examined, it is possible that there is also a
potential effect of MMP11 on urethral development.
In summary, the present study examined targets of low-dose
BPA exposure and transcriptome differences in response to BPA,
E2 and TCDD in hFFCs derived from child HS patients using
DNA microarray analysis. Of particular interest, the expression of
MMP11 was found to be downregulated by BPA in a dose-
dependent manner. Furthermore, we also found that MMP11
expression in the HS group was significantly lower than in the CO
group. Our findings suggested that the involvement of BPA in the
development of HS might relate to downregulation of MMP11
expression. Further study of the novel target genes identified in this
study during genital tubercle development might increase our
knowledge of the molecular basis of the effects of BPA on human
reproductive health.
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